Blocking antibodies against TIM-3 are currently used in combination with anti-PD-1 in a phase I/II clinical trial for patients affected by glioblastoma multiforme (www.clinicaltrials.gov, accessed on 28 March 2021). Here, PDCD1 is linked to glioblastoma.